Cytosorbents (NASDAQ:CTSO) Receives New Coverage from Analysts at StockNews.com

StockNews.com began coverage on shares of Cytosorbents (NASDAQ:CTSO) in a note issued to investors on Thursday. The firm set a “hold” rating on the medical research company’s stock.

Separately, HC Wainwright reaffirmed a “neutral” rating and issued a $1.00 price objective on shares of Cytosorbents in a research note on Friday, March 15th.

Cytosorbents Stock Up 3.8 %

NASDAQ CTSO opened at $0.84 on Thursday. The stock’s 50-day moving average price is $0.92 and its 200-day moving average price is $1.15. The company has a quick ratio of 1.51, a current ratio of 1.77 and a debt-to-equity ratio of 0.11. Cytosorbents has a 52 week low of $0.78 and a 52 week high of $4.29. The company has a market capitalization of $45.66 million, a P/E ratio of -1.31 and a beta of 0.58.

Cytosorbents (NASDAQ:CTSO) last posted its quarterly earnings data on Thursday, March 14th. The medical research company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.02. Cytosorbents had a negative return on equity of 120.24% and a negative net margin of 78.43%. The firm had revenue of $8.67 million for the quarter, compared to the consensus estimate of $9.29 million. On average, equities research analysts predict that Cytosorbents will post -0.36 earnings per share for the current year.

Institutional Trading of Cytosorbents

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Key Client Fiduciary Advisors LLC raised its stake in Cytosorbents by 188.0% during the 1st quarter. Key Client Fiduciary Advisors LLC now owns 34,557 shares of the medical research company’s stock valued at $33,000 after purchasing an additional 22,557 shares during the period. Chicago Partners Investment Group LLC raised its stake in Cytosorbents by 84.0% during the 3rd quarter. Chicago Partners Investment Group LLC now owns 36,358 shares of the medical research company’s stock valued at $67,000 after purchasing an additional 16,598 shares during the period. Raymond James & Associates bought a new stake in Cytosorbents during the 4th quarter valued at approximately $56,000. Sargent Investment Group LLC raised its stake in Cytosorbents by 4.1% during the 4th quarter. Sargent Investment Group LLC now owns 1,308,747 shares of the medical research company’s stock valued at $1,453,000 after purchasing an additional 51,699 shares during the period. Finally, Neuberger Berman Group LLC grew its holdings in Cytosorbents by 19.9% during the 4th quarter. Neuberger Berman Group LLC now owns 1,801,799 shares of the medical research company’s stock valued at $1,997,000 after buying an additional 299,103 shares in the last quarter. Institutional investors own 32.87% of the company’s stock.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.